Leptomeningeal disease: current diagnostic and therapeutic strategies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Winn, 2011, Youmans neurological surgery, 4
Deangelis, 2010, Leptomeningeal metastases in the MRI era, Neurology, 74, 1449, 10.1212/WNL.0b013e3181dc1a69
Kim, 2016, Leptomeningeal metastasis: Clinical experience of 519 cases, Eur J Cancer, 56, 107, 10.1016/j.ejca.2015.12.021
Chamberlain, 2005, Leptomeningeal metastases: current concepts and management guidelines, J Natl Compr Canc Netw, 3, 693, 10.6004/jnccn.2005.0039
Beauchesne, 2010, Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours, Lancet Oncol, 11, 871, 10.1016/S1470-2045(10)70034-6
Wen, 2017, Leptomeningeal metastases: a RANO proposal for response criteria, Neuro Oncol, 19, 484, 10.1093/neuonc/now183
Lee, 2012, Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, Lung Cancer, 76, 387, 10.1016/j.lungcan.2011.11.022
Topkan, 2016, Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors, J Neurooncol, 129, 329, 10.1007/s11060-016-2179-9
Keam, 2016, Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions, Int J Mol Sci, 17, 10.3390/ijms17071074
Forsyth, 2016, Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy, Int J Cancer, 139, 1195, 10.1002/ijc.30147
Chamberlain, 2009, Leptomeningeal metastasis, Curr Opin Neurol, 22, 665, 10.1097/WCO.0b013e3283322a92
Supe, 2013, Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy, World J Surg Oncol, 11, 55, 10.1186/1477-7819-11-55
Berger, 2012, Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors, Strahlenther Onkol, 188, 148, 10.1007/s00066-011-0025-8
Robins, 2011, Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment, Curr Cancer Ther Rev, 7, 319, 10.2174/157339411797642597
Shaw, 2013, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer, J Thorac Oncol, 8, 1570, 10.1097/JTO.0000000000000029
Glas, 2016, Therapy of leptomeningeal metastasis in solid tumors, Cancer Treat Rev, 43, 83, 10.1016/j.ctrv.2015.12.004
Portenoy, 1990, Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias, J Neurooncol, 9, 225, 10.1007/BF02341153
Jaeckle, 2006, Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment, Semin Oncol, 33, 312, 10.1053/j.seminoncol.2006.04.016
Chamberlain, 2013, Carcinomatous meningitis: Leptomeningeal metastases in solid tumors, Surg Neurol Int, 4, S265, 10.4103/2152-7806.111304
Jaeckle, 2014, Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials, Neuro Oncol, 16, 1176, 10.1093/neuonc/nou089
Posner, 1979, Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology, Neurology, 29, 1369, 10.1212/WNL.29.10.1369
Recht, 1998, Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results, Cancer, 82, 733, 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z
Twijnstra, 2000, Treatment of leptomeningeal metastases evaluated by interphase cytogenetics, J Clin Oncol, 18, 2053, 10.1200/jco.2000.18.10.2053
Kim, 2016, Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma, Ann Lab Med, 36, 209, 10.3343/alm.2016.36.3.209
Kaplan, 2015, Long term safety of sacral nerve modulation in medicare beneficiaries, Neurourol Urodyn, 34, 659, 10.1002/nau.22618
Chamberlain, 2014, CSF CA 15-3 in breast cancer-related leptomeningeal metastases, J Neurooncol, 117, 117, 10.1007/s11060-014-1361-1
Hayakawa, 1992, Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors, J Neurooncol, 12, 111
Kim, 2010, Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis, J Clin Neurol, 6, 33, 10.3988/jcn.2010.6.1.33
Felgenhauer, 1986, The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid, J Neurol, 233, 358, 10.1007/BF00313922
Connor, 2011, Detection of cancer cells in the cerebrospinal fluid: current methods and future directions, Fluids Barriers CNS, 8, 14, 10.1186/2045-8118-8-14
Chamberlain, 2013, Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series, CNS Oncol, 2, 121, 10.2217/cns.12.45
Press, 1990, Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain, Neurology, 40, 435, 10.1212/WNL.40.3_Part_1.435
Sellar, 1999, Imaging features of leptomeningeal metastases, Clin Radiol, 54, 765, 10.1016/S0009-9260(99)91181-9
DeAngelis, 1995, Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis, Ann Neurol, 38, 51, 10.1002/ana.410380111
Friedman, 1994, Gadolinium enhancement of the leptomeninges caused by hydrocephalus: a potential mimic of leptomeningeal metastasis, AJNR Am J Neuroradiol, 15, 639
Kormanik, 1996, Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases, Neurology, 46, 1674, 10.1212/WNL.46.6.1674
DeAngelis, 1998, 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases, Neurology, 50, 438, 10.1212/WNL.50.2.438
Chamberlain, 1998, Radioisotope CSF flow studies in leptomeningeal metastases, J Neurooncol, 38, 135, 10.1023/A:1005982826121
Kesari, 2012, Novel approaches to treating leptomeningeal metastases, J Neurooncol, 106, 225, 10.1007/s11060-011-0686-2
Groves, 2003, The pathogenesis of neoplastic meningitis, Curr Oncol Rep, 5, 15, 10.1007/s11912-003-0082-y
Liu, 2009, Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma, J Neurooncol, 94, 229, 10.1007/s11060-009-9819-2
Avraham, 2003, Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability, J Biol Chem, 278, 5277, 10.1074/jbc.M210063200
Gastl, 2000, Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis, Neurology, 54, 1670, 10.1212/WNL.54.8.1670
Rubenstein, 2006, Molecular pathogenesis of primary central nervous system lymphoma, Neurosurg Focus, 21, E1
Avraham, 2004, Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells, Mol Cancer Res, 2, 327, 10.1158/1541-7786.327.2.6
Singh, 2009, CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion, Br J Cancer, 100, 1638, 10.1038/sj.bjc.6605055
Murawska, 2007, Breast cancer leptomeningeal metastasis—the role of multimodality treatment, J Neurooncol, 84, 57, 10.1007/s11060-007-9340-4
Posner, 1982, Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients, Cancer, 49, 759, 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7
Lu, 2016, Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis, Oncol Lett, 12, 1301, 10.3892/ol.2016.4783
Wakelee, 2014, Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era, Clin Lung Cancer, 15, 202, 10.1016/j.cllc.2013.12.009
Omuro, 2012, Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy, J Thorac Oncol, 7, 382, 10.1097/JTO.0b013e3182398e4f
Prasad, 2016, Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy, J Neurosurg, 125, 26, 10.3171/2016.7.GKS161541
Velasco, 2012, Leptomeningeal metastases, Curr Treat Options Neurol, 14, 402, 10.1007/s11940-012-0182-9
Kormanik, 1998, Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy, Arch Neurol, 55, 506, 10.1001/archneur.55.4.506
Besse, 2017, Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era, Cancer Treat Rev, 53, 128, 10.1016/j.ctrv.2016.12.006
Howell, 1999, A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors, Clin Cancer Res, 5, 3394
Strik, 2009, Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide, Anticancer Res, 29, 5191
Heinemann, 2008, Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report, Anticancer Drugs, 19, 832, 10.1097/CAD.0b013e32830b58b0
Barstis, 2015, Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient, J Immunother Cancer, 3, 41, 10.1186/s40425-015-0084-y
Lee, 2016, Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis, Cancer Res Treat, 48, 843, 10.4143/crt.2014.234
Janin, 2016, Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer, J Clin Oncol, 34, e151, 10.1200/JCO.2012.44.8894
Levi, 1987, A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis, J Clin Oncol, 5, 1655, 10.1200/JCO.1987.5.10.1655
Elledge, 2016, Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a, Review of the Literature. Breast J, 22, 218, 10.1111/tbj.12554
Siegal, 1998, Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?, J Neurooncol, 38, 151, 10.1023/A:1005999228846
Junck, 1994, Clinical outcome in aggressively treated meningeal carcinomatosis, Arch Neurol, 51, 457, 10.1001/archneur.1994.00540170033013
Egorin, 1998, High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?, J Clin Oncol, 16, 1561, 10.1200/JCO.1998.16.4.1561
Khasawneh, 2015, Cancer metabolism and oxidative stress: Insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexate, BBA Clin, 3, 152, 10.1016/j.bbacli.2015.01.006
Bertino, 2001, Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance, Cancer Res, 61, 4599
Sun, 2017, Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas, World J Gastroenterol, 23, 516, 10.3748/wjg.v23.i3.516
Nurgali, 2017, Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches, Curr Med Chem, 24, 1537, 10.2174/0929867324666170111152436
Errihani, 2016, First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study, Pan Afr Med J, 24, 324, 10.11604/pamj.2016.24.324.4058
Abrey, 2007, Capecitabine therapy of central nervous system metastases from breast cancer, J Neurooncol, 85, 223, 10.1007/s11060-007-9409-0
Groves, 2003, Response of neoplastic meningitis from solid tumors to oral capecitabine, J Neurooncol, 65, 167, 10.1023/B:NEON.0000003752.89814.ca
Elledge, 2006, Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report, Clin Breast Cancer, 7, 164, 10.3816/CBC.2006.n.028
Ludwin, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330
Henson, 2015, Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial, JAMA, 314, 2535, 10.1001/jama.2015.16669
Gajjar, 2006, Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children, J Neurooncol, 76, 313, 10.1007/s11060-005-7409-5
Van de Nes, 2011, Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review, Eur J Med Res, 16, 415, 10.1186/2047-783X-16-9-415
Chen, 2014, Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme, J Med Imaging Radiat Oncol, 58, 714, 10.1111/1754-9485.12185
Ulbricht, 2010, A case of primary leptomeningeal gliomatosis confined to the spinal cord, J Neurooncol, 98, 125, 10.1007/s11060-009-0050-y
Nakajima, 2015, Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report, Oncol Lett, 9, 1885, 10.3892/ol.2015.2940
Cohen, 2017, Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report, J Neurosurg Spine, 1, 10.3171/2016.10.SPINE16948
Zagonel, 2011, Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma, J Neurooncol, 104, 381, 10.1007/s11060-010-0484-2
Villaflor, 2015, Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature, Dis Esophagus, 28, 772, 10.1111/dote.12276
Ilson, 2007, Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan, J Clin Oncol, 25, e14, 10.1200/JCO.2006.10.3317
O'Rourke, 2010, Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy, J Thorac Oncol, 5, 1716, 10.1097/JTO.0b013e3181f1cc32
Wolff, 2010, Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma, Pediatr Blood Cancer, 54, 180, 10.1002/pbc.22279
Dietrich, 2011, Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis, Case Rep Oncol, 4, 211, 10.1159/000327699
Gutin, 2008, Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features, Neuro Oncol, 10, 199, 10.1215/15228517-2007-058
Bruna, 2012, Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors, J Neurooncol, 109, 137, 10.1007/s11060-012-0879-3
Raizer, 2013, Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases, J Neurooncol, 112, 247, 10.1007/s11060-013-1055-0
Allen, 2002, Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy, Mol Cancer Ther, 1, 545
Ahn, 2011, Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats, Cancer Chemother Pharmacol, 68, 531, 10.1007/s00280-010-1522-7
Taphoorn, 2005, CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases, Neurology, 65, 1120, 10.1212/01.wnl.0000178981.39984.c2
Weller, 2004, Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value, Br J Cancer, 91, 219, 10.1038/sj.bjc.6601953
Lu, 2015, A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis, BMC Cancer, 15, 299, 10.1186/s12885-015-1290-1
Lu, 2016, Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis, J Formos Med Assoc, 115, 243, 10.1016/j.jfma.2015.03.005
Johnson, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884
Nishio, 2017, Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib, Anticancer Drugs, 28, 565, 10.1097/CAD.0000000000000489
Akerley, 2009, Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases, J Clin Oncol, 27, 5255, 10.1200/JCO.2009.22.0616
Damek, 2010, The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis, J Neurooncol, 96, 375, 10.1007/s11060-009-9969-2
Fruehauf, 2008, The effect of bevacizumab (Avastin) on neuroimaging of brain metastases, Surg Neurol, 70, 649, 10.1016/j.surneu.2007.06.029
Hirano, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530
Giaccone, 2012, Tyrosine kinase inhibitors in lung cancer, Hematol Oncol Clin North Am, 26, 589, 10.1016/j.hoc.2012.02.001
Yang, 2015, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis, J Thorac Oncol, 10, 1754, 10.1097/JTO.0000000000000669
Heo, 2013, Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer, J Thorac Oncol, 8, 1069, 10.1097/JTO.0b013e318294c8e8
Bang, 2009, Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI, Lung Cancer, 65, 80, 10.1016/j.lungcan.2008.10.016
Mishima, 2012, Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer, Cancer Chemother Pharmacol, 70, 399, 10.1007/s00280-012-1929-4
Kesari, 2015, A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer, Oncotarget, 6, 4527, 10.18632/oncotarget.2886
Katakami, 2015, High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs, Cancer Chemother Pharmacol, 75, 1261, 10.1007/s00280-015-2759-y
Silberman, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J Clin Oncol, 19, 3267, 10.1200/JCO.2001.19.13.3267
Baggstrom, 2017, Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases, Review of the Literature. Clin Lung Cancer, 18, 354, 10.1016/j.cllc.2017.01.013
Dickgreber, 2015, Afatinib Compassionate Use Consortium. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease, J Thorac Oncol, 10, 156, 10.1097/JTO.0000000000000380
Sugiyama, 2016, Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis, Chemotherapy, 62, 147, 10.1159/000454727
Yano, 2016, High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells, Oncotarget, 7, 3847, 10.18632/oncotarget.6758
Yang, 2016, AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases, Sci Transl Med, 8, 368ra172, 10.1126/scitranslmed.aag0976
Lynch, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448
Travis, Brambilla, Noguchi, Nicholson, Geisinger, Yatabe, Beer, Powell, Riely, Van Schil, Garg, Austin, Asamura, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011; 6:244–85. https://doi.org/10.1097/JTO.0b013e318206a221.
Wakelee, 2013, A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib, J Natl Compr Canc Netw, 11, 389, 10.6004/jnccn.2013.0054
Wilner, 2011, CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib, J Clin Oncol, 29, e443, 10.1200/JCO.2010.34.1313
Soria, 2014, LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer, J Thorac Oncol, 9, e62, 10.1097/JTO.0000000000000174
Garon, 2015, Alectinib induces a durable (> 15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis, Oncologist, 20, 224, 10.1634/theoncologist.2014-0309
Takeuchi, 2013, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study, Lancet Oncol, 14, 590, 10.1016/S1470-2045(13)70142-6
Thomas, 2016, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, 17, 452, 10.1016/S1470-2045(15)00614-2
Emeremni, 2016, Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2, J Clin Oncol, 34, 2866, 10.1200/JCO.2015.65.5936
Novello, 2016, Tackling ALK in non-small cell lung cancer: the role of novel inhibitors, Transl Lung Cancer Res, 5, 301, 10.21037/tlcr.2016.06.10
Bast, 2005, HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways, Cell Cycle, 4, 87, 10.4161/cc.4.1.1360
Smith, 2016, Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab, Breast, 26, 54, 10.1016/j.breast.2015.11.005
Seidman, 2017, Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis, Clin Breast Cancer, 17, 23, 10.1016/j.clbc.2016.07.002
Heinemann, 2007, Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anticancer Drugs, 18, 23, 10.1097/01.cad.0000236313.50833.ee
Preusser, 2013, Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis, Breast Cancer Res Treat, 139, 13, 10.1007/s10549-013-2525-y
Kumthekar, 2014, Phase I Trial of Intrathecal Trastuzumab in Her2 Positive Leptomeningeal Metastases, Neuro-Oncology, 16, v19, 10.1093/neuonc/nou237.46
Tran, 2017, Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies, Cancer Control, 24, 42, 10.1177/107327481702400106
Brandsma, 2012, Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab, J Neurol, 259, 1976, 10.1007/s00415-012-6488-4
Lee, 2015, Ipilimumab Therapy for Melanoma: A Mimic of Leptomeningeal Metastases, AJNR Am J Neuroradiol, 36, E69, 10.3174/ajnr.A4581
Besse, 2017, Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient, Lung Cancer, 108, 72, 10.1016/j.lungcan.2017.02.022
Diab, 2015, IMCT-07 Therapeutic outcomes of intrathecal interleukin-2 in metastatic melanoma patients with leptomeningeal disease (LMD), Neuro-oncology, 17, v108
Groves, 2008, Prognostic factors and outcomes in patients with leptomeningeal melanomatosis, Neuro Oncol, 10, 1010, 10.1215/15228517-2008-062
Patel, 2015, Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report, Cancer Immunol Res, 3, 1201, 10.1158/2326-6066.CIR-15-0071
Selcuklu, 2016, Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid, J Clin Oncol, 34, 2404, 10.1200/JCO.2016.66.6487
Wang, 2016, EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases, Cancer Chemother Pharmacol, 78, 1305, 10.1007/s00280-016-3155-y
Krichevsky, 2012, MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity, Neuro Oncol, 14, 689, 10.1093/neuonc/nos074
Luider, 2007, Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR, MS. Proteomics, 7, 474, 10.1002/pmic.200600719